sgp130 in Chronic Human Liver Disease

Study of IL-6 Transsignaling in Chronic Human Liver Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00770198

Enrollment

129

Registered

2008-10-09

Start date

2005-01-31

Completion date

2008-10-31

Last updated

2008-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcoholic Liver Disease, Chronic Hepatitis C Virus Infection

Keywords

liver, alcohol, HCV

Brief summary

Chronic liver disease are characterized by increased levels of plasma IL-6, but the bioactivity of this cytokine in this disease is not well known. IL-6 receptor complex is regulated by multiple receptors subunits: the soluble form of IL-6 Receptor enhance IL-6 signal by a process called trans-signaling on cells expressing few membrane IL-6 receptors. Soluble gp130 is the natural inhibitor of IL-6 trans-signaling. The aim of this study is to characterize circulating and liver levels of theses compounds of IL-6 receptor complex, to unravel the bioactivity of IL-6 in this disease.

Detailed description

Consecutive patients undergoing transjugular liver biopsies for alcoholic liver disease or hepatitis C virus infection will be included in the study to measure plasma cytokines levels, peripheral blood mononuclear cells cytokine release and liver IL-6R compounds mRNA levels.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Alcohol excess intake and suspected liver disease * Alcohol excess intake and clinical liver cirrhosis * chronic hepatitis C virus infection and suspected liver disease * chronic hepatitis C virus infection and clinical liver cirrhosis

Exclusion criteria

* other (superimposed) liver disease

Countries

Belgium

Outcome results